Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 309
6
Diseases
30
Unique genes
0.242
Avg. similarity score
Paris-trousseau thrombocytopenia
Most-connected disease (5 links)
Disease
Searched: Paris-trousseau thrombocytopenia
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Paris-trousseau thrombocytopenia
Peripheral primitive neuroectodermal tumor
bleeding disorder, platelet-type, 21
Extraskeletal ewing sarcoma
Skeletal ewing sarcoma
Congenital left-sided heart lesions
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Paris-trousseau thrombocytopenia | 5 | 5 | 1 |
| Peripheral primitive neuroectodermal tumor | 5 | 5 | 1 |
| bleeding disorder, platelet-type, 21 | 5 | 5 | 1 |
| Extraskeletal ewing sarcoma | 4 | 4 | 4 |
| Skeletal ewing sarcoma | 4 | 4 | 5 |
| Congenital left-sided heart lesions | 3 | 3 | 25 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| FLI1 | 6 / 6 | bleeding disorder, platelet-type, 21, Congenital left-sided heart lesions, Extraskeletal ewing sarcoma, Paris-trousseau thrombocytopenia and 2 more |
| ERG | 2 / 6 | Extraskeletal ewing sarcoma, Skeletal ewing sarcoma |
| EWSR1 | 2 / 6 | Extraskeletal ewing sarcoma, Skeletal ewing sarcoma |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Transcriptional misregulation in cancer | KEGG | 5 / 198 | 10.1× | 1.18e-4 | 2.65e-3 ✓ sig. |
| Glucagon-type ligand receptors | Reactome | 2 / 33 | 24.3× | 3.04e-3 | 3.18e-2 ✓ sig. |
| MASTL Facilitates Mitotic Progression | Reactome | 1 / 3 | 133× | 7.48e-3 | 5.89e-2 |
| Electric Transmission Across Gap Junctions | Reactome | 1 / 5 | 80.1× | 1.24e-2 | 8.10e-2 |
| Activation of NOXA and translocation to mitochondria | Reactome | 1 / 5 | 80.1× | 1.24e-2 | 8.10e-2 |
| Insulin secretion | KEGG | 2 / 86 | 9.3× | 1.94e-2 | 1.05e-1 |
| Platelet homeostasis | Reactome | 1 / 8 | 50.0× | 1.98e-2 | 1.06e-1 |
| Ca2+ activated K+ channels | Reactome | 1 / 9 | 44.5× | 2.23e-2 | 1.14e-1 |
| Activation of PUMA and translocation to mitochondria | Reactome | 1 / 9 | 44.5× | 2.23e-2 | 1.14e-1 |
| Pyrimidine salvage | Reactome | 1 / 11 | 36.4× | 2.71e-2 | 1.27e-1 |
| Pyrimidine catabolism | Reactome | 1 / 11 | 36.4× | 2.71e-2 | 1.27e-1 |
| The activation of arylsulfatases | Reactome | 1 / 13 | 30.8× | 3.20e-2 | 1.39e-1 |
| Elevation of cytosolic Ca2+ levels | Reactome | 1 / 13 | 30.8× | 3.20e-2 | 1.39e-1 |
| Transcriptional regulation of granulopoiesis | Reactome | 1 / 14 | 28.6× | 3.44e-2 | 1.44e-1 |
| N-Glycan antennae elongation | Reactome | 1 / 15 | 26.7× | 3.68e-2 | 1.50e-1 |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| development of primary female sexual characteristics | GO:0046545 | 2 / 4 | 311× | 1.49e-5 | 7.38e-4 ✓ sig. |
| cAMP/PKA signal transduction | GO:0141156 | 2 / 10 | 125× | 1.11e-4 | 3.38e-3 ✓ sig. |
| positive regulation of calcium ion transport into cytosol | GO:0010524 | 2 / 14 | 89.0× | 2.24e-4 | 5.64e-3 ✓ sig. |
| regulation of DNA-templated transcription | GO:0006355 | 9 / 1,454 | 3.9× | 3.25e-4 | 7.33e-3 ✓ sig. |
| regulation of transcription by RNA polymerase II | GO:0006357 | 9 / 1,602 | 3.5× | 6.65e-4 | 1.19e-2 ✓ sig. |
| neuronal action potential | GO:0019228 | 2 / 34 | 36.6× | 1.35e-3 | 1.87e-2 ✓ sig. |
| negative regulation of response to reactive oxygen species | GO:1901032 | 1 / 1 | 623× | 1.61e-3 | 2.06e-2 ✓ sig. |
| regulation of intracellular steroid hormone receptor signaling pathway | GO:0033143 | 1 / 1 | 623× | 1.61e-3 | 2.06e-2 ✓ sig. |
| somatotropin secreting cell development | GO:0060133 | 1 / 1 | 623× | 1.61e-3 | 2.06e-2 ✓ sig. |
| negative regulation of mitotic chromosome condensation | GO:1905213 | 1 / 2 | 311× | 3.21e-3 | 3.02e-2 ✓ sig. |
| mechanosensory behavior | GO:0007638 | 1 / 2 | 311× | 3.21e-3 | 3.02e-2 ✓ sig. |
| uridine catabolic process | GO:0006218 | 1 / 2 | 311× | 3.21e-3 | 3.02e-2 ✓ sig. |
| uridine metabolic process | GO:0046108 | 1 / 2 | 311× | 3.21e-3 | 3.02e-2 ✓ sig. |
| sensory perception of touch | GO:0050975 | 1 / 2 | 311× | 3.21e-3 | 3.02e-2 ✓ sig. |
| regulation of CAMKK-AMPK signaling cascade | GO:1905289 | 1 / 3 | 208× | 4.81e-3 | 3.69e-2 ✓ sig. |